Company profile: Oligomerix
1.1 - Company Overview
Company description
- Provider of target identification and validation technologies to enhance drug discovery for neurodegenerative diseases, and tau-targeting therapeutics including OLX-07010, a Phase 1 small molecule inhibitor of tau self-association, a series of tau small molecule inhibitors, and companion biomarker programs to aid diagnosis and monitoring.
Products and services
- Companion Biomarkers Programs: Tau-targeted programs developed to create biomarkers that complement tau therapeutics by aiding diagnosis and longitudinal monitoring across neurodegenerative diseases
- OLX-07010: Small molecule inhibitor of tau self-association, in Phase 1 clinical trials, preventing tau aggregation to target Alzheimer’s disease and other tauopathies
- Tau Small Molecule Inhibitors: Early-stage series of small molecules engineered to inhibit tau self-association, targeting the initial stages of tau aggregation in neurodegenerative diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oligomerix
Karuna Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical medicines for psychiatric and neurological conditions, developing treatments with a focus on schizophrenia and the behavioral symptoms of Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Karuna Therapeutics company profile →
4P-Pharma
HQ: France
Website
- Description: Provider of clinical-stage regenerating active drugs and therapies for serious diseases, including 4P004, a GLP-1 analog for osteoarthritis; 4P022, an AI platform-based treatment for systemic sclerosis; 4P025 for primary sclerosing cholangitis; 4P021, a CXCR4 antagonist for acute respiratory distress syndrome and pulmonary complications; and 4P020, a beta-3 adrenergic receptor agonist for Stargardt disease and dry age-related macular degeneration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4P-Pharma company profile →
Avid Radiopharmaceuticals
HQ: United States
Website
- Description: Provider of molecular imaging agents to aid detection and monitoring of chronic human diseases. Products include FDA-approved PET imaging agents: Amyvid for detecting beta-amyloid plaques in the brain and Tauvid for detecting tau pathology in patients evaluated for Alzheimer's disease. Based in Philadelphia, PA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avid Radiopharmaceuticals company profile →
Predix Pharmaceuticals
HQ: United States
Website
- Description: Provider of drug discovery and development leveraging a novel 3D Discovery and Optimization Engine for GPCR drug candidates. Utilizes the proprietary PREDICT algorithm to computer-model the 3D structure of any GPCR target and advance novel compounds into the clinic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Predix Pharmaceuticals company profile →
SyntheticMR
HQ: Sweden
Website
- Description: Provider of innovative magnetic resonance imaging software that supports shorter exam times and delivers more information to clinicians. Products include SyMRI NEURO for quantitative MRI with contrast images, tissue segmentation, and volumetric measurements in a single scan; SyMRI MSK for musculoskeletal imaging with quantitative maps and contrast images; and MAGiC, a GE Healthcare version offering customizable MRI imaging solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SyntheticMR company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oligomerix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oligomerix
2.2 - Growth funds investing in similar companies to Oligomerix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oligomerix
4.2 - Public trading comparable groups for Oligomerix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →